copeia

What copeia does

Copeia GmbH is a German digital health company founded in 2020 and headquartered in Bergisch Gladbach, with additional offices in Cologne and Berlin. The company develops software tools for medical cannabis therapy workflows in Germany, serving physicians, patients, pharmacies, pharmaceutical companies, and statutory health insurers (GKV). Its core products are GKV-Check:CAM and GKV-Arztfragebogen:CAM, which automate insurance reimbursement applications and physician questionnaires under the German cannabis annex of the Medicines Directive (AM-RL); Copeia Dosis EQ, a dosing and titration planning tool; PEP, a real-world evidence platform aggregating physician case studies; and a cannabis product database accessible via QR codes in the VCA pharmacy network.

The underlying technology combines rule-based clinical and regulatory workflows with AI/NLP components used to process clinical trial data, patient surveys, and research outputs related to cannabinoids and psilocybin. The company collaborates with Boston Children's Hospital, Fraunhofer IAIS, and Ben-Gurion University on research, and integrates with DocCheck for physician and pharmacist authentication. Peer-reviewed publications co-authored with these partners validate the technical approach.

The business model is freemium for end users (physicians and patients), with planned B2B monetization from pharmaceutical companies, pharmacy chains, and health insurers. Distribution leverages the Verband der Cannabis versorgenden Apotheken (VCA) network of 50+ specialized pharmacies. The company has not disclosed funding rounds, revenue, or headcount beyond a stated 1-10 employee range, indicating an early-stage operating profile with research-driven credibility but limited commercial scale.

Name

copeia

Legal name

Copeia GmbH

Website

https://copeia.info

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Copeia is a German digital health company developing software for medical cannabis therapy, including reimbursement, dosing, and real-world evidence tools that serve physicians, patients, pharmacies, and health insurers.

Ownership category

akta.pro rank

Product category

Digital Health / Medical Cannabis Software

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industries

Medical Cannabis Dispensaries (CRANAFAB), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Medical cannabis software
• Digital health platform
• Reimbursement documentation
• Titration planning tools
• Real-world evidence

Headquarters

HQ city

Bergisch Gladbach

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software / Digital Health Tools (B2B): Copeia provides digital health solutions to healthcare industry stakeholders — doctors, pharmacies, pharma companies, and health insurers — to optimize cannabis-based therapy. The company develops AI-based products and workflow solutions. Revenue appears to derive from B2B licensing/subscription arrangements with healthcare industry players rather than direct patient fees. Free tools for patients and physicians serve as acquisition/engagement mechanisms.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Copeia develops digital healthcare software for medical cannabis treatment and clinical workflows in Germany. Its product suite supports physicians with insurance reimbursement eligibility checks, structured application documentation, individual titration/dosing planning, and a physician-only real-world case documentation platform, while providing patients and pharmacies a transparent cannabis product database with batch-level QR code access. The platform combines AI/NLP-driven analytics with a growing proprietary real-world evidence repository, and the company serves healthcare industry stakeholders including pharmacies, pharma companies, and statutory health insurers through B2B arrangements.

Product overview

Copeia develops a suite of digital health solutions to support medical cannabis therapy, comprising five integrated tools: (1) GKV-Check:CAM and GKV-Arztfragebogen:CAM for streamlined insurance reimbursement assessment and application documentation; (2) Copeia Dosis EQ for individual titration planning and prescription template creation; (3) Physicians Experience Platform (PEP) as a structured Real-World database of physician case studies; and (4) CAM Database providing transparent product information and batch analysis access via pharmacy QR code partnerships. The platform supports both patients and healthcare industry stakeholders (physicians, pharmacies, pharma, insurers).

Differentiator

Problem solved

Functional benefit

Products and services

• GKV-Check:CAM A rapid, indication-specific evaluation tool that assesses prescription eligibility for medical cannabis under Germany's statutory health insurance (GKV), incorporating the legal framework and economic considerations. It is free for both physicians and patients.
• GKV-Arztfragebogen:CAM Structured questionnaire that guides healthcare professionals through all required documentation for insurance coverage applications per the German Pharmaceutical Directive (AM-RL), reducing formal errors and insurer queries. Access is restricted to medical professionals via DocCheck login.
• Copeia Dosis EQ Application enabling intuitive creation of individual titration plans and prescription templates for cannabis extracts and Dronabinol, with clear parameter visualization for complex dose calculations during initial prescription or therapy adjustments. Access via DocCheck login for medical professionals.
• Physicians Experience Platform (PEP) Structured real-world database and platform enabling physicians to document anonymized case studies of medical cannabis therapies, capturing indications, symptoms, medications, dosages, side effects, and quality of life outcomes via an interactive 9-section form. Supports case study search and comparison. Access via DocCheck login for medical professionals.
• CAM Database (Cannabis-Produkt Datenbank) Product database providing transparent overview of available cannabis medications with access to laboratory batch analyses via QR codes. In partnership with pharmacies, patients can scan QR codes to obtain detailed product-specific information including batch analysis certificates.

Quantifiable outcome

• 84% of surveyed patients reported significant improvement in quality of life under medical cannabis therapy
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Verband der Cannabis versorgenden Apotheken (VCA)coreStrategic or Co-development PartnerVCA is the German Association of Cannabis-Supplying Pharmacies. Copeia partnered with VCA to distribute survey materials through a network of 50+ member pharmacies, enabling patient recruitment for research surveys. The partnership also facilitated distribution of QR code-based product information materials to patients through pharmacies.
• Cannabis Pharmacies (partners via QR code system)coreChannel Partner/ Reseller/ DistributorCopeia partners with German cannabis pharmacies to offer a QR code system on cannabis products. Patients scan the QR code to access batch-specific analysis certificates and detailed product information. This pharmacy partnership enables the product database and patient-facing transparency tool.
• Boston Children's Hospital (Information Services Department)coreStrategic or Co-development PartnerLong-term strategic research partnership. Copeia co-authors research with staff from Boston Children's Hospital's Information Services Department. Multiple joint research publications on pharmacokinetics, sex differences in cannabinoid therapy, patient-reported outcomes, and AI/NLP methodologies. Assaf Landschaft holds positions at both organizations.
• Fraunhofer IAIS (Intelligent Analysis and Information Systems)coreStrategic or Co-development PartnerResearch partnership with Fraunhofer IAIS for AI-driven medical cannabis research. Copeia's research on leveraging patient data repositories for medical cannabinoid research was presented at MCC 2024 and indexed in the Fraunhofer Publica repository. Assaf Landschaft holds a position at Fraunhofer IAIS.
• Patient Organizations (patient advocacy groups)minorGTM or Marketing PartnerCopeia collaborates with German patient organizations to distribute survey materials and reach patients for research surveys. Patient organizations helped recruit participants for the nationwide 2022 survey, which reached 1,582 participants.
• Ben-Gurion University of the NegevminorStrategic or Co-development PartnerCopeia co-authored a systematic review of THC pharmacokinetics with researchers from Ben-Gurion University of the Negev (Department of Clinical Biochemistry and Pharmacology). David Stepensky co-authored the research.
• DocCheckcoreTechnology or IntegrationDocCheck is a German physician credentialing and authentication platform. Copeia uses DocCheck to gate access to professional tools (GKV-Arztfragebogen:CAM, Dosis EQ, PEP), ensuring that sensitive healthcare tools are accessible only to verified medical professionals.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Algea Care: German telemedicine platform focused on medical cannabis prescriptions and patient management. Direct peer because it operates in the same German medical cannabis ecosystem, serving physicians and patients with digital workflows for cannabis therapy initiation and follow-up.
• Sanity Group: Berlin-based medical cannabis company spanning cultivation, distribution, and digital health tooling for patients and physicians. Direct peer because it is Germany-domiciled and combines cannabis supply with physician/patient-facing digital services in the same regulated reimbursement environment.
• Cannify: Cannabis product recommendation and education platform (originally Denmark/US) using patient profiling to match cannabis profiles to conditions. Direct peer because it shares Copeia's evidence-driven, structured-data approach to cannabis therapy decision support, even if delivery is via web rather than physician workflow.

Regional players

• Kanna Health (formerly KannaMed): German medical cannabis provider combining pharmacy distribution with patient digital services. Regional peer because it shares the German cannabis pharmacy ecosystem with Copeia and overlaps on patient education and access, though less focused on physician workflow tooling.

Broad incumbents

• Leafly Holdings: Largest global cannabis information platform with strain, product, and dispensary data plus patient/provider content. Broad incumbent peer because it shares the 'cannabis knowledge + discovery' layer of the patient journey that Copeia addresses through CAM Database and PEP.
• Weedmaps / WM Technology: US-listed cannabis marketplace connecting consumers, retailers, and brands with software and data layers. Broad incumbent peer because it operates at the intersection of dispensary software, product transparency, and patient-facing information — adjacent to Copeia's pharmacy-linked product database.
• IQVIA: Global leader in clinical research, real-world evidence, and healthcare data analytics serving pharma and life sciences. Broad incumbent peer because Copeia's PEP-based RWE ambitions and AI clinical-trial pipeline overlap with IQVIA's eCOA/CTMS/RWE franchise, even though IQVIA operates across all of healthcare.
• Flatiron Health: Oncology-focused real-world evidence and EHR-linked data platform acquired by Roche. Broad incumbent peer because its core play — aggregating structured clinician-documented cases into a research-grade dataset — is the same model Copeia is building for cannabis at a smaller scale.
• Doctolib: Dominant European digital health platform for appointment booking, teleconsultation, and physician workflow software across Germany, France, and Italy. Broad incumbent peer because Doctolib sits upstream of cannabis prescribing workflows and could plausibly bundle cannabis-specific decision support if the category scales.

Emerging players

• Caresyntax: Berlin-based AI-powered surgical and clinical data platform that aggregates structured perioperative data for outcomes research. Emerging player peer because it shares Copeia's playbook of using structured clinical data capture + AI/NLP to build evidence-rich datasets from frontline clinicians, though in surgery rather than cannabis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/copeia

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about copeia